Molecular and Cellular Pharmacology, Vol 6, No 3 (2014)

FDA Approves Viekira Pak to Treat Hepatitis C

Abstract

The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis...….(click PDF to read more)

Full Text: PDF